Multimodal action of phosphodiesterase 5 inhibitors against neurodegenerative disorders: An update review.

Autor: Singh NK; Division of Pharmacology, Institute of Pharmaceutical Research, GLA University, Chaumuhan, Mathura, India., Singh P; Division of Pharmacology, Institute of Pharmaceutical Research, GLA University, Chaumuhan, Mathura, India., Varshney P; Division of Pharmacology, Institute of Pharmaceutical Research, GLA University, Chaumuhan, Mathura, India., Singh A; Division of Pharmacology, Institute of Pharmaceutical Research, GLA University, Chaumuhan, Mathura, India., Bhushan B; Division of Pharmacology, Institute of Pharmaceutical Research, GLA University, Chaumuhan, Mathura, India.
Jazyk: angličtina
Zdroj: Journal of biochemical and molecular toxicology [J Biochem Mol Toxicol] 2024 Nov; Vol. 38 (11), pp. e70021.
DOI: 10.1002/jbt.70021
Abstrakt: Phosphodiesterase type 5 (PDE5) is an enzyme primarily found in the smooth muscle of the corpus cavernosum and also highly expressed in the substantia nigra, cerebellum, caudate, hippocampal regions and cerebellar purkinje cells, responsible for selectively breaking down cyclic guanosine monophosphate (cGMP) into 5'-GMP and regulate intracellular cGMP levels. As a second messenger, cyclic GMP enhances signals at postsynaptic receptors and triggers downstream effector molecules, leading to changes in gene expression and neuronal responses. Additionally, cGMP signaling transduction cascade, present in the brain, is also essential for learning and memory processes. Mechanistically, PDE5 inhibitors share structural similarities with cGMP, competitively binding to PDE5 and inhibiting cGMP hydrolysis. This action enhances the effects of nitric oxide, resulting in anti-inflammatory and neuroprotective effects. Neurodegenerative disorders entail the progressive loss of neuron structure, culminating in neuronal cell death, with currently available drugs providing only limited symptomatic relief, rendering neurodegeneration considered incurable. PDE5 inhibitors have recently emerged as a potential therapeutic approach for neurodegeneration, neuroinflammation, and diseases involving cognitive impairment. This review elucidates the principal roles of 3',5'-cyclic adenosine monophosphate (cAMP) and cGMP signaling pathways in neuronal functions, believed to play pivotal roles in the pathogenesis of various neurodegenerative disorders. It provides an updated assessment of PDE5 inhibitors as disease-modifying agents for conditions such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, cerebral ischemia, Huntington's disease, and neuroinflammation. The paper aims to review the current understanding of PDE5 inhibitors, which concurrently regulate both cAMP and cGMP signaling pathways, positing that they may exert complementary and synergistic effects in modifying neurodegeneration, thus presenting a novel direction in therapeutic discovery. Moreover, the review provides critical about biological functions, therapeutic potentials, limitations, challenges, and emerging applications of selective PDE5 inhibitors. This comprehensive overview aims to guide future academic and industrial endeavors in this field.
(© 2024 Wiley Periodicals LLC.)
Databáze: MEDLINE
Externí odkaz: